REPL
Price
$12.92
Change
-$0.32 (-2.42%)
Updated
Sep 11 closing price
Capitalization
1.22B
47 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$58.65
Change
-$0.15 (-0.26%)
Updated
Sep 11 closing price
Capitalization
5.68B
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REPL vs XENE

REPL vs XENE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
REPL vs. XENE commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a Hold and XENE is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($5.68B) has a higher market cap than REPL($1.22B). REPL YTD gains are higher at: 32.922 vs. XENE (30.857). REPL has higher annual earnings (EBITDA): -284.22M vs. XENE (-439.19M). XENE has more cash in the bank: 931M vs. REPL (195M). XENE has less debt than REPL: XENE (6.42M) vs REPL (112M). REPL (0) and XENE (0) have equivalent revenues.
REPLXENEREPL / XENE
Capitalization1.22B5.68B21%
EBITDA-284.22M-439.19M65%
Gain YTD32.92230.857107%
P/E RatioN/AN/A-
Revenue00-
Total Cash195M931M21%
Total Debt112M6.42M1,745%
FUNDAMENTALS RATINGS
REPL vs XENE: Fundamental Ratings
REPL
XENE
OUTLOOK RATING
1..100
6084
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
10025
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3544
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
4375

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (54) in the Biotechnology industry is in the same range as XENE (79). This means that REPL’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (25) in the Biotechnology industry is significantly better than the same rating for REPL (100). This means that XENE’s stock grew significantly faster than REPL’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as REPL (99). This means that XENE’s stock grew similarly to REPL’s over the last 12 months.

REPL's Price Growth Rating (35) in the Biotechnology industry is in the same range as XENE (44). This means that REPL’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for REPL (100). This means that XENE’s stock grew significantly faster than REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REPLXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 11 days ago
76%
Bullish Trend 10 days ago
69%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
70%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (REPL: $12.92 vs. XENE: $58.65)
Brand notoriety: REPL and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REPL: 83% vs. XENE: 49%
Market capitalization -- REPL: $1.22B vs. XENE: $5.68B
REPL [@Biotechnology] is valued at $1.22B. XENE’s [@Biotechnology] market capitalization is $5.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 0 FA rating(s) are green while XENE’s FA Score has 2 green FA rating(s).

  • REPL’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • REPL’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, REPL is a better buy in the short-term than XENE.

Price Growth

REPL (@Biotechnology) experienced а -14.10% price change this week, while XENE (@Biotechnology) price change was -1.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

REPL is expected to report earnings on Oct 29, 2026.

XENE is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
REPL
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HERO27.260.63
+2.38%
Global X Video Games & Esports ETF
NBIE27.150.27
+1.00%
Neuberger International Core Equity ETF
DIVG37.800.33
+0.88%
Invesco S&P 500 Hi Div Grwrs ETF
TLT80.870.09
+0.11%
iShares 20+ Year Treasury Bond ETF
KORP45.250.01
+0.02%
American Century Dvrs Corp Bd ETF

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-2.42%
IMNN - REPL
57%
Loosely correlated
+1.38%
SNDX - REPL
49%
Loosely correlated
-3.40%
KYMR - REPL
45%
Loosely correlated
-1.74%
NRIX - REPL
43%
Loosely correlated
-2.75%
ZYME - REPL
42%
Loosely correlated
-0.74%
More